Select Medical Holdings (SEM)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Select Medical Holdings.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
52-Week Range
Current price 16.60 $ — 98% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -4.9% failed
- More than 10% revenue growth is expected for the coming year 4.6% failed
- Share count grows by less than 3% a year -0.3% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 10.8% failed
- Gross margin at 40% or higher and without meaningful erosion 11.5% failed
- Goodwill from acquisitions does not grow faster than revenue 40.4% passed
- Net debt below twice EBITDA 6.9 x EBITDA failed
- Operating cash flow covers the profits of the last three years 843 m passed
- Return on capital at 15% or higher, or up versus two years ago 6.9% failed
- Insiders hold at least 10% or are net buyers 16.0% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 0.6% below the current price.
- Consensus
- Sell
- Analyst Ratings
- 6
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1.22 | 1.11 – 1.30 | 5,701 | 5.6% | 5 |
| 12/31/2027 | 1.38 | 1.26 – 1.50 | 5,971 | 13.0% | 4 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.12 | -133.20 | -123 | -110.10 | – | 125 | 62 |
| 2025: Q1 | 0.45 | -42.60 | 1,353 | -24.40 | 4.20 | -4 | -56 |
| 2025: Q2 | 0.33 | -47.40 | 1,340 | 4.50 | 3.00 | 110 | 46 |
| 2025: Q3 | 0.23 | -47.70 | 1,363 | -22.60 | 2.10 | 175 | 122 |
| 2025: Q4 | 0.16 | – | 1,397 | – | 1.40 | 64 | 5 |
| 2026: Q1 | 0.36 | -20.70 | 1,422 | 5.00 | 3.10 | -4 | -56 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 4,286 | 300 | 115 | 0.90 | 347 | 906 | 4,944 |
| 2017 | 4,444 | 356 | 177 | 1.37 | 238 | 933 | 5,127 |
| 2018 | 5,081 | 417 | 138 | 1.06 | 494 | 916 | 5,964 |
| 2019 | 5,454 | 472 | 148 | 1.14 | 445 | 771 | 7,340 |
| 2020 | 5,532 | 568 | 259 | 2.00 | 1,028 | 1,060 | 7,655 |
| 2021 | 6,205 | 714 | 402 | 3.09 | 401 | 1,110 | 7,360 |
| 2022 | 6,334 | 403 | 159 | 1.28 | 285 | 1,122 | 7,665 |
| 2023 | 6,664 | 555 | 243 | 1.98 | 582 | 1,288 | 7,690 |
| 2024 | 5,187 | 268 | 214 | 1.72 | 518 | 1,681 | 5,608 |
| 2025 | 5,453 | 335 | 146 | 1.18 | 346 | 1,706 | 5,852 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Select Medical Holdings Corporation betreibt über ihre Tochtergesellschaften Reha-Krankenhäuser für kritische Erkrankungen, Rehabilitationskrankenhäuser und ambulante Rehabilitationskliniken in den USA. Das Segment Critical Illness Recovery Hospital umfasst Krankenhäuser, die Leistungen für Herz…
| Employees | 30,800 |
|---|---|
| Headquarters | Mechanicsburg, PA |
| Address | 4714 Gettysburg Road, 17055 Mechanicsburg, United States |
| Phone | 717 972 1100 |
| Website | selectmedical.com |
| IPO Date | 25. Sep 2009 |
| ISIN | US81619Q1058 |
| Stock Split | 232:125 on 11/26/2024 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Robert A. Ortenzio | Co-Founder & Executive Chairman | 1958 |
| Thomas P. Mullin | Chief Executive Officer | 1984 |
| John A. Saich | President | 1969 |
| Michael F. Malatesta | Executive VP & CFO | 1970 |
| Martin F. Jackson | Senior Executive Vice President of Strategic Finance & Operations | 1955 |
| Christopher S. Weigl | Senior VP, Controller & Chief Accounting Officer | 1984 |
| Brian R. Rusignuolo | Executive VP & Chief Information Officer | 1976 |
| Robert G. Breighner Jr. | Senior Vice President of Compliance & Audit | 1969 |
| John F. Duggan | Executive VP, General Counsel & Secretary | 1964 |
| Bridget Sherick | Senior Vice President of Accounting for Shared Services | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.